Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc. (SRPT) is a publicly traded US company. Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.

The company reports trailing twelve-month revenue of $730.80M and net income of $330.96M.

Key metrics include a return on equity of 22.0%, a debt-to-equity ratio of 1.11.

Investors tracking SRPT can follow price movements, analyst estimates, and fundamental changes directly through FINOTAUR's research tools.